Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,270 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04551495 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) | unknown | Phase 2 | 65 | Jules Bordet InstituteOTHER | 2 | Dec 4, 2024 | clinicaltrials |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT02236910 | An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours | unknown | Phase 2 | 66 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06586697 | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | unknown | Phase 2 | 20 | The Center for Clinical and Cosmetic ResearchOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT03612232 | Cabozantinib in Advanced Adrenocortical Carcinoma(CaboACC) | unknown | Phase 2 | 37 | Wuerzburg University HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05182866 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | unknown | Phase 2 | 9 | Rakuten Medical, Inc.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT04524208 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3(CABONEN) | unknown | Phase 2 | 45 | Karsten GavenisOTHER | 2 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | unknown | Phase 2 | 38 | Zhujiang HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06540937 | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04483284 | Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | unknown | Phase 2 | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530784 | Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | unknown | Phase 2 | 21 | West China HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05389527 | Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma(NeoLeap-HCC) | unknown | Phase 2 | 43 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06355037 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04562337 | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC | unknown | Phase 2 | 67 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06090656 | Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)(BEST) | unknown | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | unknown | Phase 1 / Phase 2 | 93 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05964101 | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma(GALAXY-1) | unknown | Phase 2 | 25 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma(NAPSTER) | unknown | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2025source: clinicaltrials